Lorna Tanner is a partner in the Intellectual Property Practice Group in the firm’s Silicon Valley and San Francisco offices and is the former leader of the firm’s Life Sciences team.
Areas of Practice
Lorna develops global patent portfolios for drugs and biologics. Her practice is centered on counseling dynamic startups and mid-size pharma companies. She has a highly focused practice that aligns patent portfolios for late stage and approved therapeutics with specific business needs, such as product launch, asset acquisition, and third party challenges. She performs due diligence analyses on patent portfolios for financings, mergers and acquisitions, and renders opinions on infringement, inventorship, and freedom-to-operate.
Lorna’s technical emphasis is in pharmaceutically active small molecules in clinical development with a primary focus on developing and executing patent strategies for late-stage and approved drugs. She has experience in a variety of other technologies, including: biologics such as antibodies, modified proteins and viruses; biopolymers; drug delivery, including pulmonary, topical, and pharmaceutical formulations; and medical devices, including aesthetic devices, syringes, catheters and embolic coils. Lorna also has experience with green technologies and agricultural products.
- Gilead Sciences, Inc. - Prosecuting numerous patent portfolios directed to hepatitis C and cardiovascular approved drugs and drugs in development.
- Global Blood Therapeutics, Inc. - Developing and prosecuting patent portfolio directed to voxelotor and other
compounds in the pipeline.
- Denali Therapeutics, Inc. - Prosecuting numerous patent portfolios directed to several targets.
- Portola Pharmaceuticals, Inc. – Developing and prosecuting patents directed to anticoagulant drugs and biologics.
- Plexxikon Inc. – Developing and prosecuting patents directed to oncology drugs and drug candidates.
- Outside patent counsel to publicly traded biopharma company, prosecuting patents relating to drug candidates for treating anemia.
- Outside patent counsel to numerous emerging biopharma companies developing and prosecuting patents directed to drug discovery assays, medical devices and combination drug products.
Patent Strategy Attorney of the Year - California, LMG Life Sciences, 2021
The World's Leading Patent Professionals, IAM Patent 1000, 2019, 2021
Patent IP Star, Managing Intellectual Property, 2020-2021
Intellectual Property Star, Patent Strategy & Management, LMG Life Sciences, 2019
Top Intellectual Property Lawyers, Daily Journal, 2018-2019
Women Leaders in Tech Law, The Recorder, 2017
Recognized for patent prosecution work, Legal 500, 2011
- Co-author, "America Invents Act: Law & Analysis," Wolters Kluwer, 2012
Intellectual Property Law Blog Posts
- "Federal Circuit Confirms Addition of Two Inventors of Groundbreaking Immunotherapies for Cancer," July 15, 2020
- "Congress Gives Patent and Trademark Office Temporary Authorization to Move Deadlines in Light of COVID-19 Pandemic" March 27, 2020
- "Federal Circuit Weighs in on Patent Subject-Matter Eligibility of Dietary Supplements," March 21, 2019
"PTO Cancer Immunotherapy Fast Track," July 14, 2016
- Global Legal Chronicle, 09.25.2018
- Women Leaders in Tech Law: Lorna Tanner, Sheppard MullinThe Recorder, 10.02.2017
- Law360, 08.13.2013
- Presented by UCSF-CTSI Catalyst Awards, 09.16.2014
J.D., Santa Clara University School of Law, 2002, Articles Editor of the Santa Clara Computer and High Technology Law Journal
B.S., University of California, Berkeley, 1999
- U.S. Patent and Trademark Office
- U.S. District Court for the Northern District of California
- U.S. Court of Appeals for the Ninth Circuit
- U.S. Court of Appeals for the Federal Circuit